Ann Arbor

SkySpecs announces expanded solution offering to simplify renewable energy asset management.

Retrieved on: 
Wednesday, December 8, 2021
Engineering, Financial services, GLOBE, Climate change, Conference, Growth, Operation, SALT, CPO, Efficiency, CMS, Rover, Maintenance, SPV, Finance, Solution, Wind, Software as a service, Renewable energy, Asset management, Risk management

SALT LAKE CITY, UT, Dec. 08, 2021 (GLOBE NEWSWIRE) -- SALT LAKE CITY, UT (December 8, 2021) SkySpecs CEO Danny Ellis today announced the launch of SkySpecs expanded suite of asset management solutions for renewable energy.

Key Points: 
  • SALT LAKE CITY, UT, Dec. 08, 2021 (GLOBE NEWSWIRE) -- SALT LAKE CITY, UT (December 8, 2021) SkySpecs CEO Danny Ellis today announced the launch of SkySpecs expanded suite of asset management solutions for renewable energy.
  • There is a huge need for clean, renewable energy but it needs to be produced more efficiently, said Ellis.
  • Come by our booth at 627 if you would like to learn more about our new renewable energy asset management solutions.
  • SkySpecs is simplifying renewable energy asset management by offering purpose-built technologies and services that help our customers deliver industry-leading productivity, efficiency and returns.

Esperion Announces Closing of $225 Million Public Offering

Retrieved on: 
Tuesday, December 7, 2021
U.S. Securities and Exchange Commission, Twitter, Forward-looking statement, Company, File, Research, GLOBE, SEC, Security (finance), Park, ESPR, Patient, ANN, SEC filing, LLC, COVID-19, NASDAQ, Sale, Telephone, Cholesterol

At closing, Esperion received net proceeds from the offering of approximately $208.8 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Key Points: 
  • At closing, Esperion received net proceeds from the offering of approximately $208.8 million, after deducting underwriting discounts and commissions and estimated offering expenses.
  • All of the securities sold in the offering were offered by Esperion.
  • Esperion intends to use the net proceeds from the offering to fund the ongoing commercialization efforts for NEXLETOL and NEXLIZET, research and clinical development of current or additional pipeline candidates, and general corporate purposes.
  • H.C. Wainwright & Co. acted as sole book-running manager for the public offering.

Esperion Announces Pricing of $225 Million Public Offering

Retrieved on: 
Friday, December 3, 2021
Patient, Security (finance), Cholesterol, Sale, Forward-looking statement, ESPR, Company, Exercise, SEC filing, SEC, U.S. Securities and Exchange Commission, Telephone, COVID-19, ANN, Park, Prospectus, Twitter, Research, GLOBE, LLC, File, NASDAQ

ANN ARBOR, Mich., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (Esperion or the Company), today announced the pricing of its previously announced underwritten public offering of 32,142,858 shares of its common stock and short-term warrants to purchase up to an aggregate of 32,142,858 shares of common stock.

Key Points: 
  • ANN ARBOR, Mich., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (Esperion or the Company), today announced the pricing of its previously announced underwritten public offering of 32,142,858 shares of its common stock and short-term warrants to purchase up to an aggregate of 32,142,858 shares of common stock.
  • All of the securities being sold in the offering are being offered by Esperion.
  • The offering is expected to close on or about December7, 2021, subject to satisfaction of customary closing conditions.
  • This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including, without limitation, statements related to the completion of the public offering, the satisfaction of customary closing conditions related to the public offering and the intended use of proceeds from the public offering.

Esperion Announces Proposed Public Offering

Retrieved on: 
Thursday, December 2, 2021
Patient, Security (finance), Cholesterol, Sale, Forward-looking statement, ESPR, Company, SEC filing, SEC, U.S. Securities and Exchange Commission, Telephone, COVID-19, ANN, Park, Prospectus, Twitter, Research, GLOBE, LLC, File, NASDAQ

All of the securities to be sold in the offering are to be offered by Esperion.

Key Points: 
  • All of the securities to be sold in the offering are to be offered by Esperion.
  • H.C. Wainwright & Co. is acting as sole book-running manager for the proposed public offering.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including, without limitation, statements related to the terms, timing and completion of the proposed public offering, the satisfaction of customary closing conditions related to the proposed public offering and the intended use of proceeds from the proposed public offering.

Wisely Reveals New Ways for Restaurants to Leverage Data to Grow Their Business and Deliver an Exceptional Guest Experience

Retrieved on: 
Monday, November 29, 2021
CEO, Technology, Software as a service, Acquisition, Marketing, Customer engagement, First Watch, VP, CDP, ANN, Restaurant, Wine, GLOBE, Innovation, GM, Ecosystem, Automation, 3D printing, Retail

Changs, and Matt Eisenacher, SVP Brand Strategy and Innovation at First Watch, about maximizing customer lifetime value with customer intelligence.

Key Points: 
  • Changs, and Matt Eisenacher, SVP Brand Strategy and Innovation at First Watch, about maximizing customer lifetime value with customer intelligence.
  • The 60-minute virtual release event will introduce a variety of new ways to personalize guest communications, deliver a meaningful dining experience, and keep team members informed.
  • Our new features make it easier than ever for restaurant brands to collect, analyze, and act on their dataand, ultimately, provide an exceptional guest experience.
  • Changs, and hundreds more to personalize the guest experience to maximize customer lifetime value and build a profitable future with data.

Esperion Presents Important New Science Highlighting Potential Benefits of NEXLETOL® (bempedoic acid) Tablets at American Heart Association Scientific Sessions 2021

Retrieved on: 
Friday, November 12, 2021

ANN ARBOR, Mich., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of three abstracts highlighting NEXLETOL tablets at the American Heart Association (AHA) Scientific Sessions 2021 taking place on November 13-15, 2021.

Key Points: 
  • These presentations provide important new information for clinicians as they look to provide oral therapies to reduce LDL-C, said Dr. JoAnne Foody, chief medical officer of Esperion.
  • Overall, from baseline to Week 12, BA lowered LDL-C levels comparable to that of a moderate- or high-intensity statin ( 30%) in 28.9% of patients.
  • In patients not receiving background statins, greater than 50% of patients achieved at least 30% LDL-C lowering with BA.
  • In these studies, NEXLETOL provided an average of 18% placebo-corrected LDL-C lowering when used with moderate or high-intensity statins.

Home Point Capital Reports Third Quarter 2021 Financial Results

Retrieved on: 
Thursday, November 4, 2021

ANN ARBOR, Mich., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Home Point Capital Inc. (NASDAQ: HMPT) (“Home Point Capital” or the “Company”), the parent entity of Home Point Financial Corporation (“Homepoint”), today announced its financial results for the third quarter ended September 30, 2021.

Key Points: 

Esperion Reports Third Quarter 2021 Financial Results and Provides Company Update

Retrieved on: 
Tuesday, November 2, 2021
Guideline, Twitter, U.S. Securities and Exchange Commission, Cardiovascular disease, Cleveland, Â, Daiichi Sankyo, Research and development, COVID-19, Program, Therapy, GLOBE, Ezetimibe, Research, CVD, Security (finance), Moyamoya disease, Atherosclerosis, Tablet, Stroke, Administration, Physician, Pharmacy, Hypercholesterolemia, Bempedoic acid, Cholesterol, National Cholesterol Education Program, Treasury, Exercise, Risk, Esperion Therapeutics, Disease, CEO, Environment, Growth, Population, MACE, General officer, Patient, ANN, Prescription, ESPR, NASDAQ, Quarter, Adult, Forward-looking statement, Development, Mortality, Pharmaceutical industry, Animal, Lithium, Risk management

ANN ARBOR, Mich., Nov. 02, 2021 (GLOBE NEWSWIRE) --  Esperion (NASDAQ: ESPR) today reported financial results for the third quarter ended September 30, 2021 and provided a business update.

Key Points: 
  • Royalty revenue for the third quarter 2021 was $1.2 million and $2.8 million for the nine months ended September 30, 2021.
  • The increase in total revenue in the third quarter of 2021 was primarily attributable to prescription growth of NEXLETOL and NEXLIZET.
  • The decrease in the third quarter of 2021 was primarily attributable to a decrease in commercial compensation expense.
  • Esperion will host a conference call and webcast today, November 2, 2021 at 8:00 A.M. Eastern Time to provide a third quarter 2021 financial results and company update.

Esperion to Present Key Science at the American Heart Association Scientific Sessions 2021

Retrieved on: 
Monday, November 1, 2021
Pregnancy, Kidney, Atrial fibrillation, Drug, Anemia, Abdominal pain, Upper respiratory tract infection, Cholesterol, Bronchitis, Twitter, Simvastatin, Tendon rupture, Fetus, Gout, Patient, Clinical trial, Spasm, Moyamoya disease, U.S. Securities and Exchange Commission, Rotator cuff, Sino-Japanese Journalist Exchange Agreement, Risk, Back pain, Pravastatin, Lactation, Disease, Uric acid, Pharmacokinetics, Diet, Safety, Rupture, Esperies, Pain, Shoulder, Mortality, Achilles tendon, Pharmaceutical industry, Dietary supplement

Limitations of Use: The effect of bempedoic acid on cardiovascular morbidity and mortality has not been determined.

Key Points: 
  • Limitations of Use: The effect of bempedoic acid on cardiovascular morbidity and mortality has not been determined.
  • Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.
  • Tendon Rupture: Bempedoic acid is associated with an increased risk of tendon rupture or injury.
  • The inclusion of forward-looking statements should not be regarded as a representation by ESPERION that any of these results will be achieved.

ADI Awarded Contract to Refresh NOAA Satellite Systems With the ADEPT Software Platform

Retrieved on: 
Monday, November 1, 2021
Science, Government, Certification, National Ocean Service, NOAA, A&D, COTS, Weather, ADI, Life, Social media, Internet, Maintenance, Unitary state, Environment, IOT, News, National Oceanic and Atmospheric Administration, Private sector, GLOBE, Linux, Longevity, ANN, ADEPT, Water, Risk management

By leveraging new hardware and the ADEPT industrial computing platform, this project will add cybersecurity hardening and extend the serviceable life of these systems by well over a decade.

Key Points: 
  • By leveraging new hardware and the ADEPT industrial computing platform, this project will add cybersecurity hardening and extend the serviceable life of these systems by well over a decade.
  • "ADI is excited to partner with NOAA on this project.
  • By utilizing the ADEPT software platform, NOAA will have a trusted commercial partner that can provide support and maintenance on these systems throughout their service lifetime and beyond.
  • To learn more about how ADI and the ADEPT platform can help your team, visit www.adi.com or send an email to [email protected] .